CAPITALAB Secures $46 Million Funding to Revolutionize OTC Derivatives Solutions

We are thrilled to announce that CAPITALAB has successfully raised an impressive $46 million in our latest funding round. As a leading provider of innovative solutions for users of OTC Derivatives—including investment banks, hedge funds, and various financial institutions—CAPITALAB is committed to transforming the way these entities optimize their portfolios and manage risk. This substantial influx of capital will enable us to further enhance our cutting-edge technology and analytical tools, designed to significantly reduce capital requirements while minimizing both credit and operational risks associated with market activities. As a division of BGC Brokers L.P., we understand the complexities and challenges that financial institutions face in today’s dynamic market landscape. With this new funding, we aim to not only expand our service offerings but also invest in research and development. Our goal is to deliver even more sophisticated solutions that empower our clients to thrive in an increasingly competitive environment. We are excited about the opportunities that lie ahead and are eager to leverage this funding to solidify our position as a market leader in OTC derivatives management. Thank you to all of our investors for believing in our vision and for their continued support. Together, we are poised to make a lasting impact on the financial industry, fostering greater efficiency and risk mitigation for our clients and driving sustainable growth in the process. Stay tuned as we embark on this exciting journey!